- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00331058
Comparison Of Molecular Targets In Mild To Severe Asthmatics And Healthy Subjects
A Study To Validate Key Therapeutic Targets and Characterise Their Response to Corticosteroids in Multiple Asthma Phenotypes
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27103
- GSK Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Male or female subjects aged between 18-60 years inclusive at screening.
- A female subject of childbearing potential must be using effective contraceptive
- measures described in protocol for at least one month prior to Screening and should continue using the same contraceptive measure during the study until completion of follow-up procedures. Non child-bearing potential is defined as pre-menopausal females with documented (medical report verification) hysterectomy or surgical sterilisation, or post-menopausal women who have been amenorrheic for more than 1 year and having estradiol and FSH levels consistent with menopause.). Other methods include male partner who is sterile prior to female subject's entry into study and is the sole sexual partner for that female subject.
- Atopic or non-atopic subjects
- Able to comprehend the nature of this research protocol and other relevant medical information and the ability to give written informed consent prior to participation in the study.
- Able to comply with the requirements and restrictions listed in the consent form.
- Available to complete the study and all measurements.
- Read, comprehend, and write English at a sufficient level to complete study related materials.
Additional inclusion criteria for the steroid naïve intermittent asthmatics - Cohort A
- Have a pre-history of a physician's diagnosis of asthma, with exclusion of other significant pulmonary
- No significant disease other than asthma.
- No history of steroid myopathy.
- No history of recent exposure to live vaccine in the past 4 weeks and no intention to undergo live vaccination during the prednisolone trial or during the month following the trial.
- Intermittent asthma with FEV1 ≥ 80% predicted.
- Positive beta agonist reversibility as shown by greater than 12% improvement on FEV1or greater than 200ml improvement in FEV1 within 30 minutes following the administration of Albuterol Inhalation Aerosol OR a positive PC20 to Methacholine Challenge smaller than 16 mcg.
- Not currently taking inhaled steroids (ICS), and has not taken ICS for at least 6 months prior to screening.
- A non-smoker (as demonstrated by a negative urine cotinine) for at least the past 12 months with a pack history ≤5 pack years.
Additional inclusion criteria for the mild to moderate persistent asthmatics on regular inhaled steroids - Cohort B
- Have a pre-history of a physician's diagnosis of asthma, with exclusion of other significant pulmonary diseases
- No significant disease other than asthma.
- No history of steroid myopathy.
- No history of recent exposure to live vaccine in the past 4 weeks and no intention to undergo live vaccination during the prednisolone trial or during the month following the trial.
- Mild to moderate persistent asthmatic with FEV1 ≥ 80% predicted
- Asthma symptoms ranging from daily to less than once a day
- Positive beta agonist reversibility as shown by greater than 12% improvement on FEV1or greater than 200ml improvement in FEV1 within 30 minutes following the administration of Albuterol Inhalation Aerosol OR a positive PC20 to Methacholine Challenge smaller than 16 mcg.
- On regular inhaled steroid treatment (from 200-500 mcg FP daily or equivalent). Short and long acting beta-2 agonists, anti-cholinergies, and Leukotriene receptor antagonists are allowed as concurrent medication.
- A non-smoker (as demonstrated by a negative urine cotinine) for at least the past 12 months with a pack history ≤5 pack years.
Additional inclusion criteria for the severe persistent asthmatics on maximal therapy; regular oral steroids - Cohort C
- Have a pre-history of a physician's diagnosis of asthma, with exclusion of other significant pulmonary diseases
- No significant disease other than asthma.
- No history of steroid myopathy.
- No history of recent exposure to live vaccine in the past 4 weeks and no intention to undergo live vaccination during the prednisolone trial or during the month following the trial.
- Severe persistent asthmatic
Subjects should have at least one (if on oral steroids) or two (if only on inhaled steroids) of the following indices:
- FEV1 <80% (post bronchodilator) and FEV1/FVC ratio <70% predicted;
- Daily symptoms ± nocturnal symptoms as recorded in diary cards during run-in;
- severe exacerbations (as defined FACET study Tattersfield 1999) of ≥ twice a year in at least one of the last two years, as recorded in clinical records
- Positive beta agonist reversibility as shown by greater than 12% improvement on FEV1 or greater than 200ml improvement in FEV1 within 30 minutes following the administration of Albuterol Inhalation Aerosol OR a positive PC20 to Methacholine Challenge smaller than 16 mcg.
- High dose inhaled steroids (≥ to 1000 mcg FP daily or equivalent), oral steroids of ≤ 20mg prednisolone a day or equivalent.
- A non-smoker (as demonstrated by a negative urine cotinine) for at least the past 12 months with a pack history ≤5 pack years.
Additional inclusion criteria for the currently smoking, mild to moderate persistent asthmatics on maximal therapy; regular oral steroids - Cohort D
- Have a pre-history of a physician's diagnosis of asthma, with exclusion of other significant pulmonary
- No significant disease other than asthma.
- No history of steroid myopathy.
- No history of recent exposure to live vaccine in the past 4 weeks and no intention to undergo live vaccination during the prednisolone trial or during the month following the trial.
- Smokers (as demonstrated by a positive urine cotinine) with a pack history >5 pack years
- Mild to moderate persistent asthmatic with FEV1 ≥ 80% predicted
- Asthma symptoms less than once a day
- Positive beta agonist reversibility as shown by greater than 12% improvement on FEV1or greater than 200ml improvement in FEV1 within 30 minutes following the administration of Albuterol Inhalation Aerosol OR a positive PC20 to Methacholine Challenge smaller than 16mcg.
- On regular inhaled steroid treatment (200-500 mcg FP daily or equivalent). (NB:
short and long acting beta-2 agonists, anti-cholinergies, and Leukotriene receptor antagonists are allowed as concurrent medication.) Additional inclusion criteria for healthy volunteers, non asthmatic, non smokers - Cohort E Healthy; defined as individuals who are free of significant cardiovascular, pulmonary (e.g. tuberculosis), gastrointestinal, hepatic, endocrine, renal, haematological, neurological and psychiatric disease as determined by medical history, physical examination and clinical chemistry/haematology/urinalysis investigation.
• A non-smoker (as demonstrated by a negative urine cotinine) for at least the past 12 months with a pack history ≤5 pack years.
Exclusion criteria:
- As a result of medical interview, physical examination or screening investigation the physician responsible considers the subject unfit for the study.
- The subject has a history of drug or other allergy, which, in the opinion of the responsible physician, contra-indicates their participation.
- Subject is female who is pregnant or lactating.
- Having participated within 30 days or 5 half-lives in a study receiving an investigational drug.
- Having participated within 30 days in a study with an invasive procedure.
- Donation of a 500 mL of blood within the previous 56 days or intention to donate within 56 days of the end of the last bronchoscopy.
- Evidence of recent infection that would preclude participation in the steroid trial in the judgement of the study physician. The subject may be deferred to later participation. History of abnormal bruising or bleeding.
- History of alcohol or drug abuse within five years.
- Positive urine test for drugs of abuse including alcohol at screen.
- Abnormal (clinically significant) clinical laboratory test results.
- Medical history of cirrhosis, hepatitis C or hepatitis B or HIV
- Doing night-shift work that will change pattern within at least 5 days prior to study start through the first follow up visit for Cohorts A through D. This does not include the follow up visits at 6 and 12 months.
- Female subjects who are unwilling or unable to use an appropriate method of contraception
- Those who, in the opinion of the investigator, have a risk of non-compliance with study procedures.
- Concomitant medications that may interfere with study procedures or evaluations.
- History of hypersensitivity to any of the following medications: Lidocaine, Fentanyl, Versed, Demerol, Midazolam, Epinephrine, Flumanzenil and Naloxon.
- History of hypersensitivity to bronchodilator (such as Albuterol)
- ALL WOMEN OF CHILD BEARING POTENTIAL WHO DO NOT WISH TO USE PROTOCOL APPROVED METHODS OF CONTRACEPTION WILL BE EXCLUDED.
Additional exclusion criteria for the steroid naïve intermittent asthmatics - Cohort A
- Subject has changed asthma medication within 1 month prior to screening.
- Subject had an asthma exacerbation in the previous month.
- Known sensitivity or allergy to prednisolone.
- History of tuberculosis, glaucoma, epilepsy, severe affective disorder or peptic ulceration.
- Current use or use within the previous 1 month of oral corticosteroids.
- Current use of any asthma medication except short acting inhaled β2 agonists
- Current use of Methotrexate, cyclosporin, PDE inhibitors, azathioprine or other immunosuppressive agents, except steroids.
Additional exclusion criteria for the mild to moderate persistent asthmatics on regular inhaled steroids - Cohort B
- Subject has changed asthma medication within 1 month prior to screening.
- Subject had an asthma exacerbation in the previous month.
- Known sensitivity or allergy to prednisolone.
- History of tuberculosis, glaucoma, epilepsy, severe affective disorder or peptic ulceration.
- Current use or use within the previous 1 month of oral corticosteroids.
- Current use of Methotrexate, cyclosporin, PDE inhibitors, azathioprine or other immunosuppressive agents, except steroids.
Additional exclusion criteria for the severe persistent asthmatics on maximal therapy; regular oral steroids - Cohort C
- Subject has changed asthma medication within 1 month prior to screening.
- Subject had an asthma exacerbation in the previous month.
- Known sensitivity or allergy to prednisolone.
- History of tuberculosis, glaucoma, epilepsy, severe affective disorder or peptic ulceration.
- Current use or use within the previous 1 month of oral prednisolone or equivalent of greater than 20mg daily.
- Current use of Methotrexate, cyclosporin, PDE inhibitors, azathioprine or other immunosuppressive agents, except steroids.
- Subjects should avoid any medications that in the opinion of the physician might interfere with either the safety of the subject or the interpretation of the results (e.g.
anti-inflammatory drugs)
Additional exclusion criteria for the currently smoking, mild to moderate persistent currently smoking asthmatics on regular inhaled steroids - Cohort D
- Subject has changed asthma medication within 1 month prior to screening.
- Subject had an asthma exacerbation in the previous month.
- Known sensitivity or allergy to prednisolone.
- History of tuberculosis, glaucoma, epilepsy, severe affective disorder or peptic ulceration.
- Current use or use within the previous 1 month of oral corticosteroids.
- Current use of Methotrexate, cyclosporin, PDE inhibitors, azathioprine or other immunosuppressive agents, except steroids.
Additional exclusion criteria for the healthy volunteers, non asthmatic non smokers - Cohort E The subject has any history of breathing problems in adult life (i.e. history of asthmatic symptoms). Screening lung function tests (FEV1) will be performed to confirm normal lung function parameters (≥80% predicted).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: healthy volunteers
control group not receiving prednisolone
|
Asthmatic Volunteers
|
Other: asthmatic volunteers
receive prednisolone for 14-16 days
|
Healthy and Asthmatic Volunteers
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
compare key drug targets across 4 asthma phenotypes and healthy subjects
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
evaluate changes in target expression in response to a 2 week course of corticosteroids across the 4 asthma phenotypes
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Histopathology on bronchial biopsies
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Cytospins
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
target protein expression
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
target expression in the blood
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
inflammatory markers
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
lung function
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Radiological Parameters
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Quality of life (QoL) and symptom scores
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Changes in medication
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Measures of pulmonary inflammation
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Assessments of lung structure
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
activation state of a signalling pathway
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Whole Blood TaqMan and/or transcriptomic analysis
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
new targets and biomarkers
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
TaqMan and/or Differential Gene Expression and Proteomics
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Pharmacogenomics from blood samples
Time Frame: visits 3 through to and including visit 6
|
visits 3 through to and including visit 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisolone
Other Study ID Numbers
- RES100767
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Prednisolone
-
Children's Hospital of PhiladelphiaCompleted
-
Assiut UniversityCompleted
-
Hamamatsu UniversityCompletedChronic Disease | Eosinophilic PneumoniaJapan
-
Sparrow PharmaceuticalsRecruitingPolymyalgia RheumaticaGermany
-
IsalaCompletedChronic Obstructive Pulmonary DiseaseNetherlands
-
Institute of Child HealthUnknown
-
Postgraduate Institute of Medical Education and...Completed
-
Postgraduate Institute of Medical Education and...CompletedPost COVID-19 Diffuse Lung DiseaseIndia
-
Nanjing University School of MedicineCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity Medical Center Groningen; Imperial College London; University Hospitals... and other collaboratorsTerminatedWegener's Granulomatosis | Microscopic PolyangiitisUnited Kingdom